Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Reports Higher Third-Quarter Results, Raises 2021 Forecast to Reflect Increased COVID-19 Therapy Sales

10/26/2021 | 10:01am EST


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
12/03FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
RE
12/03Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T..
MT
12/03Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI..
MT
12/03FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant..
DJ
12/03Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in ..
MT
12/03The U.S.Food and Drug Administration Authorizes Lilly's Bamlanivimab with Etesevimab as..
CI
12/03AbCellera Biologics Names New Chief Commercial Officer
MT
12/03Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem..
MT
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin..
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 517 M - -
Net income 2021 6 130 M - -
Net Debt 2021 12 164 M - -
P/E ratio 2021 36,4x
Yield 2021 1,34%
Capitalization 222 B 222 B -
EV / Sales 2021 8,52x
EV / Sales 2022 8,33x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 245,11 $
Average target price 273,63 $
Spread / Average Target 11,6%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY45.17%222 215
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ABBVIE INC.13.40%214 815